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Membrane proteinLipid bilayer membrane is the main site where Bcl-xL executes its anti-apoptotic function. Here we used site-
directed mutagenesis and cysteine-directed cross-linking to trap the structure of Bcl-xL upon membrane
insertion. Cys151 on α5-helix and Asn185 on α6-helix of two neighboring Bcl-xL are found in close positions,
respectively. The FRET based binding assay indicated that the BH3-peptide binding pocket in Bcl-xL is
disrupted after its membrane insertion. Co-immunoprecipitation experiments showed that the membrane-
bound Bcl-xL sequestered tBid by direct interaction at physiological pH. If Bcl-xL behaves similarly at low pH
as it does at physiological pH, the membrane-bound Bcl-xL should bind to tBid through protein regions other
than the BH3 domain of tBid and the hydrophobic pocket of Bcl-xL. Previously, a crystallography study
demonstrated that Bcl-xL formed homodimers through domain swapping in water, where Cys151 and
Asn185 of two monomeric subunits are far apart from each other and the BH3-peptide binding pocket is
intact. Our results indicated that Bcl-xL dimer trapped by cross-linking in lipids is distinct from the domain
swapped dimer, suggesting that Bcl-xL transits through a structural change from the water-soluble state to
the membrane-bound state and there are multiple possibilities for structural reorganization of Bcl-xL protein.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
The normal function of apoptosis is maintained by the regulation
of anti-apoptotic and pro-apoptotic proteins of Bcl-2 family. Anti-
apoptotic proteins share four homology motifs termed Bcl-2 homolgy
(BH) domains (i.e., BH1–BH4), whereas pro-apoptotic proteins
contain either multiple BH domains or single BH3 domain. Despite
their opposite roles in apoptosis, anti-apoptotic proteins such as Bcl-2,
Bcl-xL, and pro-apoptotic proteins with multiple BH domains such as
Bax adopt similar folding [1–3]. All of them comprise two central
helices surrounded by several amphipathic helices, which resembles
the ion-channel domains of colicins and diphtheria toxin [2].
Accordingly, Bcl-2, Bcl-xL and Bax have been shown to form pores in
synthetic lipid vesicles or isolated membranes [4–7]. However, Bax
forms pores that permeabilize mitochondrial outer membranes, while
the pores formed by Bcl-xL do not allow the pass of cytochrome c. Bcl-
xL was found to compete with Bax for binding to tBid and the lipid
membranes, leading to an inhibition of the mitochondrial permeabi-
lization process [8,9].itol; FRET, ﬂuorescence reso-
s; PAGE, polyacrylamide gel
+86 21 50807088.
ll rights reserved.As the lipid bilayer membrane is the main site where Bcl-2 family
proteins execute their functions, probing their structures and events
in membranes is important for elucidating the mechanism of their
functions. Previously, lipid vesicles have been employed to study the
molecular events of Bcl-2 and Bax [10,11]. The use of the cell-free
system has recapitulated the characteristics of the pore-forming Bcl-2
family proteins observed in apoptotic cells, such as migration to
membranes [12] and oligomerization [13], and addressed the core
mechanism of membrane permeabilization by Bax [11]. Using lipid
vesicles, Thuduppathy et al. [14] also demonstrated that acidic pH
facilitates the membrane insertion of Bcl-xL, while high concentra-
tions of NaCl decreased its membrane insertion. As shown by circular
dichroism spectroscopy, membrane insertion of Bcl-xL was associated
with changes in protein structure. Speciﬁcally, tryptophan residues
insert deeply into the bilayer of the lipid vesicles as determined by a
ﬂuorescence quenching technique using phospholipids brominanted
at different positions along the acyl chain. Moreover, O'Neill et al. [15]
had puriﬁed Bcl-xL homodimer by size exclusion chromatography
(SEC) in the absence of detergents or membrane components. In the
resolved crystal structure of the dimeric protein, Bcl-xL exchanges C-
terminal regions including α6-helix between monomeric subunits.
Both BH3 peptide binding pockets are intact in the domain swapped
dimer and available for interaction with the BH3 domain of pro-
apoptotic proteins. The domain swapped dimer has increased pore
forming activity compared with monomer. Yet it is unknownwhether
Bcl-xL dimerizes through domain swapping in membranes.
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brane region of Bcl-xL and Bax had been shown to be involved in
membrane insertion [16,17], little information is available about their
packing architectures in membranes. In this work, we used site-
directed mutagenesis and chemical cross-linking to probe the
interaction sites between Bcl-xL in lipid vesicles. Cys151 on α5-helix
and Asn185 on α6-helix of two neighboring Bcl-xL are found in close
positions, respectively. Furthermore, we also found that the BH3-
peptide binding pocket in Bcl-xL was disrupted after its membrane
insertion. tBid might bind to membrane-bound Bcl-xL through the
interactions of protein regions other than the BH3 domain of tBid and
the hydrophobic pocket of Bcl-xL. Together, the present study
provides new information about the structural transition of Bcl-xL
upon membrane insertion and would help understand the mecha-
nism of Bcl-2 family proteins in membranes.
2. Materials and methods
2.1. Recombinant protein expression and puriﬁcation
Double-sites mutation of Bcl-xL (C151A/N185C) and Bcl-xL
(C151A/F143C)was performed on Bcl-xL (C151A) expression plasmid,
which was constructed from the plasmid for C-terminal 22 residues
truncated Bcl-xL on pET32b vector. The forward primers for N185C and
F143C mutation were 5′-CCTTGGATCCAGGAGTGCGGCGGCTGGGA-
TAC-3′ and 5′-GTCGCATTGTGGCCTGTTTCTCCTTCGGCGG-3′, respec-
tively. The backward primers are complementary to the forward
primers. The mutagenesis was performed using QuikChange site-
directed mutagenesis kit (Catalog No. 200519, Stratagene Ltd.). The
plasmids were conﬁrmed by DNA sequence analysis. The protein
expression and puriﬁcation for C-terminal His-tagged Bcl-xL and its
mutant proteins were carried out as described previously [18].
2.2. Preparation of Bcl-xL (C151A/N185C) disulﬁde bond dimer
40 μM Bcl-xL (C151A/N185C) was incubated with 1% (w/v) Triton
X-100 and CuP (0.4 mM CuSO4, 1.6 mM phenanthroline) in 20 mM
Tris buffer (pH 8.0) for 1 h at 37 °C. The disulﬁde bond dimer was
puriﬁed by gel ﬁltration with a Superdex 75 column. The column was
pre-equilibrated with 2 column volumes of phosphate buffered saline
buffer (PBS, 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM
KH2PO4, pH 7.4). 2 mL protein sample was loaded and eluted with PBS
at a ﬂow rate of 1 mL/min. After gel ﬁltration, the residual
concentration of Triton X-100 in the protein preparation was
measured by the method of H. S. Garewal and determined to be
under the detection limit of the method which is about 0.01% (w/v)
[19].
2.3. Circular dichroism (CD) spectroscopy
Proteins were dialyzed in sodium phosphate buffer (15.5 mM
Na2HPO4, 4.5 mM NaH2PO4, pH 7.4). CD spectra were recorded in the
range of 180–250 nm at room temperature on a JASCO 810 spectro-
polarimeter (JASCO Corporation, Japan). The molar ellipticity was the
average of ﬁve time scans in a quartz cuvette of 0.1 cm path-length
and the background signal from the buffer was subtracted.
2.4. Preparation of large unilamellar vesicles (LUV)
60% dioleoyl phophatidylcholine and 40% dioleoyl phosphatidyl-
glycerol were mixed together in chloroform and dried under a stream
of nitrogen gas. The lipids were suspended in 20 mM sodium acetate
buffer (pH 4.9) and subjected to 10 times of freeze–thaw cycles and
extruded through a 0.1-μmpolycarbonate ﬁlter 10 times tomake LUV.2.5. Pore formation of Bcl-xL and Bcl-xL (C151A/N185C)
To prepare calcein-encapsulated liposomes, lipid mixture was
suspended with 40 mM calcein in 20 mM sodium acetate buffer (pH
4.9). Non-entrapped calcein was removed by passing through a PD-10
desalting column (Catalog No. 17-0851-01, Amersham Biosciences
Ltd.). 0.5 μM protein samples were added into 125 μM calcein-
encapsulated LUV. Immediately, the ﬂuorescence at 520 nm (excited
at 490 nm) was monitored for 10 min. For the pore formation assay of
Bcl-xL (C151A/N185C) dimer, 0.5 μM protein was mixed with 125 μM
calcein-encapsulated LUV. After 1 h of incubation at 37 °C, 10 mMDTT
was added and the ﬂuorescence was monitored for 10 min. The
release of calcein was expressed as the percentage of the maximum
ﬂuorescence change of 125 μMLUV after addition of 0.1% (w/v) Triton
X-100.
2.6. Fluorescence spectroscopy of Bcl-xL and dimeric Bcl-xL
(C151A/N185C) in LUV
1 μM Bcl-xL or Bcl-xL (C151A/N185C) dimer was mixed with
various concentrations of LUV (2–500 μM, pH 4.9). After 1 h of
incubation at 37 °C, the ﬂuorescence at 300–400 nm (excited at
280 nm)was recorded in a 5×5mmquartz cuvette on a Hitachi F2500
ﬂuorescence spectrophotometer (Hitachi, Tokyo). The molar fraction
partition coefﬁcient (Kx) was calculated by ﬁtting the experiment data
to the following equation using Origin 7.0 (OriginLab Corp., http://
www.originlab.com) [20]
F =
Kx L½ 
W½  + Kx L½ 
Fbound − Ffreeð Þ + Ffree ð1Þ
where F is the ﬂuorescence of proteins at 336 nm with particular
concentrations of lipids; [L] and [W] are the molar concentrations of
lipid and water, respectively; and Fbound and Ffree are the ﬂuorescence
of proteins with excessive amount of lipids and in the absence of
lipids. The standard free energy (ΔGx0) of transfer from water to lipids
was calculated using Eq. (2).
ΔG0x = − RT ln Kx ð2Þ
R and T are the gas constant (i.e., 1.987×10−3 kcal·mol−1·K−1) and
the absolute temperature in Kelvin, respectively.
2.7. Binding activity of Bcl-xL with BH3 domain peptide
AEDANS-labeled Bak BH3 domain peptide (sequence:
SQVGRQLAIIGDDICR) was prepared as before [21]. 4 μM Bcl-xL
monomer or domain swapped dimer was mixed with 10 μM
AEDANS-labeled BH3 peptide. After 1 h of incubation at room
temperature, the ﬂuorescence at 300–550 nm was recorded (excited
at 280 nm). The ﬂuorescence from 10 μM AEDANS-labeled BH3
peptide was subtracted as the background. For the binding assay of
Bcl-xL in LUV, 4 μM Bcl-xL monomer or domain swapped dimer was
incubated with 1 mM LUV (pH 4.9) at 37 °C for 1 h prior to the
addition of 10 μM AEDANS-labeled BH3 peptide.
2.8. Cysteine-directed cross-linking of Bcl-xL and its mutant proteins
in LUV
40 μMBcl-xL, Bcl-xL (C151A/N185C), Bcl-xL (C151A/F143C) or Bcl-
xL domain swapped dimer was incubated with 10 mM LUV (pH 4.9)
for 1 h at 37 °C. CuP was added to the samples and allowed to react for
1 h at room temperature. The reaction was stopped by addition of 2×
SDS-PAGE sample buffer that contains 20 mM N-ethylmaleimide and
20 mM EDTA. The reaction product was analyzed by 10% SDS-PAGE in
the absence of reducing agents.
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3.1. Cys151 on α5-helix and Asn185 on α6-helix are at the binding
interface of Bcl-xL subunits in liposomes
It was reported that acidic pH (pHb5.0) beneﬁts the insertion of
Bcl-xL into lipid vesicles [4]. The binding of Bcl-xL with lipid vesicles
however could be decreased by over 60% as the concentration of NaCl
was increased to 500mM [14]. Thus, we conducted the lipids insertion
experiments of Bcl-xL at pH 4.9 with 20 mM sodium acetate buffer. As
shown in Fig. 1A, the ﬂuorescence of Bcl-xL is increased upon its
association with lipid vesicles, suggesting that the tryptophans such
as Trp137, Trp169 and Trp181 are inserted into the hydrophobic
environment of LUV [14]. By titrating Bcl-xL with various concentra-
tions of lipid vesicles, we found that the ﬂuorescence intensity
reached the plateau at the lipids to protein ratio of 250, indicating that
almost all the Bcl-xL has been associated with lipid vesicles in the
presence of 250 folds of lipids. This result is consistent with a previous
report that almost all the Bcl-xL binds to LUV upon addition of 200
folds of lipid vesicles [14]. Therefore, we performed the membrane
insertion and pore formation assay of Bcl-xL with 250 folds of lipids.
To map the binding interface of Bcl-xL subunits in LUV, cysteine-
directed cross-linking was used to explore Bcl-xL residues at the
interface. Cysteine-directed cross-linking has been successfullyFig. 1. Bcl-xL underwent conformational change during membrane insertion. Bcl-xL
monomer (A) or Bcl-xL (C151A/N185C) dimer (B) was mixed with various concentra-
tions of LUV (pH 4.9). After 1 h of incubation at 37 °C, the ﬂuorescence excited at
280 nm was recorded. Insets are the ﬂuorescence intensity at 336 nm plotted against
the concentration ratio of lipids to proteins.
Fig. 2. Cys151 onα5-helix of Bcl-xL or Cys185 onα6-helix of Bcl-xL (C151A/N185C) can
be cross-linked in LUV, indicating that Cys151 or Asn185 of one Bcl-xL subunit is in close
position to Cys151 or Asn185 of another Bcl-xL subunit in lipids. Bcl-xL (A), Bcl-xL
(C151A/N185C) (B), Bcl-xL (C151A/F143C) (C), and Bcl-xL domain swapped dimer (D)
were analyzed by 10% SDS-PAGE without any reducing agent. Protein was incubated in
LUV (pH 4.9). CuP was added to the samples and allowed for reaction for 1 h.applied to study the molecular architecture of membrane protein
complex. For instance, SecYEG is a protein complex that mediates the
translocation and membrane integration of proteins in Escherichia
coli. To probe the interaction sites between the subunits of SecYEG
complex on the membrane, cysteines were introduced into trans-
membrane segments of SecY and SecE [22]. If the Cβ atoms of the
cysteines of two subunits are in the range of 3–4 Å, they can form a
disulﬁde bond at oxidizing conditions of CuP (0.4 mM CuSO4, 1.6 mM
phenanthroline) [23]. By this approach, speciﬁc residues at the
interface between SecY and SecE were identiﬁed. Similarly, cyste-
ine-directed cross-linking was used in our present study to map the
binding interface of Bcl-xL subunits in lipids. Speciﬁcally, Bcl-xL was
incubated with 250 folds of LUV followed by reaction with membrane
permeant oxidative, CuP. As shown in Fig. 2A (lane 4), two major
bands near 45 kDa and 66 kDa, corresponding to two isoforms of Bcl-
xL disulﬁde bond dimers [18], appear after incubation of the liposome-
bound Bcl-xL with CuP. This result is consistent with a previous report
that Bcl-2 forms SDS-resistant dimer after incubation with liposomes
at pH 5.0 [10]. Since the protein was incubated with 250 folds of LUV
before the oxidization, the disulﬁde bond must be formed in the
liposomes. In fact, only negligible disulﬁde bond dimer was detected
in the absence of LUV (Fig. 2A, lane 2), conﬁrming that the disulﬁde
bond dimer is formed in liposomes. As Bcl-xL has only one cysteine
(Cys151) residue and located in the α5-helix (Fig. 3A), it must be at
the binding interface of Bcl-xL subunits in membranes.
To further map the residues at the binding interface, we
substituted Cys151 with alanine and changed other possible residues
Fig. 3. The crystal structures of Bcl-xL monomer (PDB code: 1MAZ) (A) and Bcl-xL homodimer (PDB code: 2B48) (B) are rendered as cartoon. Cys151 onα5-helix and Asn185 onα6-
helix are rendered in sticks. The helices are labeled for the green subunit of the dimeric protein.
Fig. 4. Mutation and disulﬁde bond formation do not affect the secondary structure of
Bcl-xL. (A) Bcl-xL (C151A/N185C) was mixed with 1% Triton X-100 and CuP. After 1 h of
incubation at 37 °C, the sample was analyzed by 10% SDS-PAGE without any reducing
agent. (B) CD spectra of Bcl-xL and its mutant proteins in sodium phosphate buffer
(15.5 mM Na2HPO4, 4.5 mM NaH2PO4, pH 7.4).
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we found that Bcl-xL (C151A/N185C) could form disulﬁde-bound
dimer in the presence of LUV and CuP (Fig. 2B). In contrast, the
incubation with LUV and CuP does not induce the disulﬁde bond
dimer formation of Bcl-xL (C151A/F143C) (Fig. 2C), which excludes
the possibility that the disulﬁde bond dimer formation of Bcl-xL and
Bcl-xL (C151A/N185C) is due to non-speciﬁc cross-linking of cysteine
residues arising from a general unfolding of Bcl-xL in liposomes.
Therefore, the disulﬁde bond formation of Bcl-xL and Bcl-xL (C151A/
N185C) in LUV indicates that Cys151 on α5-helix and Asn185 on α6-
helix are at the binding interface of two neighboring Bcl-xL subunits.
Meanwhile, it was reported that the domain swapped dimer of Bcl-
xL could insert into the synthetic membranes and form pores as Bcl-xL
monomer [15]. To explore whether the domain swapped dimer can be
cross-linked after membrane insertion, Bcl-xL dimeric protein puriﬁed
by SECwas treatedwith LUV and CuP. As shown in Fig. 2D (lane 4), the
domain swapped dimer also forms disulﬁde bond after incubation
with LUV and CuP.
3.2. Bcl-xL (C151A/N185C) disulﬁde bond dimer binds to LUV as
efﬁciently as wild type Bcl-xL
Previously, we have reported that non-ionic detergents such as 1%
Triton X-100 promotes Bcl-xL disulﬁde bond dimer formation [18].
Addition of CuP can accelerate the process. As for Bcl-xL (C151A/
N185C), incubation with 1% Triton X-100 and CuP induces nearly all
the protein to form disulﬁde bond dimer (Fig. 4A). Taking advantage
of this property, we puriﬁed the disulﬁde bond dimer of Bcl-xL
(C151A/N185C) by gel ﬁltration to remove Triton X-100 and residual
monomeric protein.
To characterize the possible conformational change introduced by
the mutation or disulﬁde bond formation, we dialyzed Bcl-xL, Bcl-xL
(C151A), Bcl-xL (C151A/N185C) and dimeric Bcl-xL (C151A/N185C) in
sodium phosphate buffer and compared their far-UV CD spectra. As
shown in Fig. 4B, the CD spectrum of Bcl-xL (C151A/N185C) disulﬁde
bond dimer is the same as those of Bcl-xL, Bcl-xL (C151A) and
monomeric Bcl-xL (C151A/N185C), indicating that the mutation and
disulﬁde bond formation do not affect the secondary structure of Bcl-xL
(C151A/N185C) protein.
To examine whether the disulﬁde bond formation affects the
lipids insertion of Bcl-xL (C151A/N185C), we studied the association
of Bcl-xL (C151A/N185C) disulﬁde bond dimer with LUV by
ﬂuorescence titration experiment. As shown in Fig. 1B, Bcl-xL
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4.9. 250 folds of LUV can bind almost all the disulﬁde bond dimeric
protein. To quantitatively compare the association of Bcl-xL and
dimeric Bcl-xL (C151A/N185C) protein with LUV, the titration curves
were ﬁtted to Eq. (1) to calculate the molar fraction partition
coefﬁcients Kx, which is in proportion with the concentration ratio
of the protein in lipids and in water. The molar fraction partition
coefﬁcients Kx for Bcl-xL and dimeric Bcl-xL (C151A/N185C) are
4.6×105 and 3.7×105, respectively. The similar Kx values indicate that
Bcl-xL and dimeric Bcl-xL (C151A/N185C) protein have similar
distribution between lipids and water. Moreover, the changes in the
standard free energy in the lipid insertion (ΔG) are −7.075 and
−6.962 kcal/M for Bcl-xL and dimeric Bcl-xL (C151A/N185C),
respectively. This result also proves that the disulﬁde bond formation
has little effect on the membrane insertion of Bcl-xL protein.3.3. Bcl-xL (C151A/N185C) disulﬁde bond dimer reversibly inactivates
the pore formation
To study whether Bcl-xL mutant proteins can form pores in lipid
vesicles, we added the proteins into 250 folds of calcein-encapsulated LUV.
As shown in Fig. 5A, Bcl-xL (C151A) induces the calcein release at a slower
speed than the wild-type Bcl-xL. The sequence alignment analysis of Bcl-2
family proteinswithmultiple BHdomains indicates that Cys151of Bcl-xL is
not a conserved residue. Although Cys151 is substituted by Ala or Val inFig. 5. Bcl-xL and its mutants can form pores in LUV. (A) 5Bcl-xL, 4Bcl-xL (C151A/N185C),
3Bcl-xL (C151A) or 2Bcl-xL (C151A/N185C) dimer was added to calcein-encapsulated LUV
(pH 4.9). Immediately, the ﬂuorescence at 520 nm (excited at 490 nm)wasmonitored for
10 min. 1PBS was used as control. (B) 2Bcl-xL (C151A/N185C) dimer was mixed with
calcein-encapsulated LUV (pH 4.9). After 1 h of incubation at 37 °C, 10mMDTTwas added
and theﬂuorescencewasmonitored for 10min. 1PBSwith 10mMDTTwas usedas control.Mcl-1 or Bax, both proteins adopt the similar folding as Bcl-xL. Thus, the
mutation of C151A in Bcl-xL is unlikely to alter the protein folding.
Consistently, the CD spectra suggest that the secondary structure of Bcl-xL
(C151A) is thesameas thatofBcl-xL (Fig. 4B).On theotherhand, thecrystal
structure of Bcl-xL shows that Cys151 formshydrophobic interactionswith
Leu13, Phe27, Val163, and Ile166. If the mutation of C151A has any effect,
thatwouldbedestabilizationof theprotein structure,which shouldbeneﬁt
thepore formation [24]. In fact, themutation reduces thepore forming rate.
Therefore, the slower pore forming rate of Bcl-xL (C151A) appears not due
to altered protein structure. It may be explained by the fact that the
mutation has changed the polarity of a residue on the pore-forming α5-
helix. A similar phenomenon was observed with the pore formation of
Bacillus thuringiensis Cry1Aa toxin [25].
Notably, though Bcl-xL (C151A/N185C) disulﬁde bond dimer adopts
the same conformation (Fig. 4B) and binds to LUV as efﬁciently as wild-
type Bcl-xL (Fig. 1), it does not release calcein from LUV while its
monomeric protein can (Fig. 5A). A possible explanation is that the
liposome-bound Bcl-xL must go through a series of conformational
changes in lipids before its pore formation [26,27]. The disulﬁde bond
may trap Bcl-xL (C151A/N185C) in an intermediate structure so that it
cannot complete the further conformational change to form pores in
lipid vesicles. Interestingly, treatment of the liposome-bound Bcl-xL
(C151A/N185C) disulﬁde bond dimer with DTT can activate the release
of the calcein (Fig. 5B). Substantial poring activity is recovered after the
reduction of Bcl-xL (C151A/N185C) disulﬁde bond dimer in LUV.
3.4. BH3 domain peptide does not bind to membrane-bound Bcl-xL
Apoptosis is regulated by the count balance of anti-apoptotic and
pro-apoptotic proteins through their heterodimerization [28,29]. It is
proposed that the BH3 domain of pro-apoptotic proteins is critical for
the heterodimerization events [30,31]. Bcl-xL complex structures
demonstrate that the BH3 domain peptides derived from pro-
apoptotic proteins bind into the hydrophobic groove constituted by
BH3, BH1 and BH2 domain residues of Bcl-xL [32,33]. However, it
remains elusive whether Bcl-xL keeps the architecture of the BH3-
peptide binding pocket and binds BH3 domain peptides after its
membrane insertion. To address this question, a FRET-based binding
assay was employed to assess the binding activity of Bak BH3-peptide
with Bcl-xL in LUV [21]. For reference, the binding of AEDANS-labeled
BH3 peptide into Bcl-xL brings about a ﬂuorescence emission at
490 nm due to the FRET occurred between Trp137, Trp181 and Trp188
in Bcl-xL and the AEDANS on the BH3-peptide (Fig. 6). In contrast, no
ﬂuorescence of AEDANS at 490 nm was observed after incubation
with 250 folds of LUV, suggesting that the BH3 domain peptide did notFig. 6. The hydrophobic pocket in Bcl-xL for binding BH3 domain of pro-apoptotic
proteins is disrupted upon its insertion in LUV. Bcl-xL monomer or domain swapped
dimer was incubated with LUV (pH 4.9) at 37 °C for 1 h. AEDANS-labeled Bak BH3
peptide was added to the proteins. After 1 h of incubation at room temperature, the
ﬂuorescence at 300–550 nm excited at 280 nm was recorded.
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swapped Bcl-xL dimer can bind the Bak BH3-peptide as reference
indicated [15], whereas the domain swapped dimer loses the binding
ability after its membrane insertion (Fig. 6).
4. Discussion
Bcl-xL, Bcl-2 and Bax share remarkably similar structures that
resemble the pore-forming domains of diphtheria toxin and colicins.
In vitro experiments demonstrated that they could form pores in
synthetic lipids membranes [4–6,34,35]. The involvement of the two
central helices, i.e. α5- and α6-helices, in the pore formation of Bcl-2
family proteins have been proved by site-directed and deletion
mutagenesis studies [36–38]. Solid-state NMR study revealed that the
C-terminal tail truncated Bcl-xL inserted α5- and α6-helices in the
membrane, while the other helices folded up to rest on the membrane
surface [39]. The multi-spanning conformation of Bcl-2 characterized
by insertion ofα5,α6-helices into themembranes was also conﬁrmed
at cellular level [26,27]. The only cysteine residue of Bcl-2, Cys158,
became embedded in membranes during apoptosis and protected
from labeling by membrane impermeant thiol-reactive probe IASD.
All above experiments are conducted at physiological pH levels.
Actually, Bcl-2 family proteins retain certain important properties at
low pH levels. For example, insertion ofα5-helix was again conﬁrmed
by monitoring the ﬂuorescence change from NBD labeled at Cys158 of
Bcl-2 after mixingwith liposome at pH 5.0 [10]. Thus, the experiments
at low pH levels may tell us something important about the properties
of Bcl-xL in connection with its function.
Herein, we demonstrated that the homologous cysteine residue in
Bcl-xL, Cys151, is at the binding interface of Bcl-xL subunits in lipid
vesicles. Moreover, we also found that Bcl-xL (C151A/N185C) can
form disulﬁde-bound dimer at oxidative condition in LUV. Therefore,
Asn185 on α6-helix is also at the binding interface of Bcl-xL subunits
in synthetic lipids. Since (1) the mutation does not affect protein
secondary structure (Fig. 4B) and (2) the disulﬁde bond dimer
formation of Bcl-xL and Bcl-xL (C151A/N185C) is not due to non-
speciﬁc cross-linking of cysteine residues (Fig. 2), the disulﬁde-bound
dimer should reﬂect the authentic architecture of Bcl-xL in
membranes.
Consistent with our results, a previous study showed that mixing
Bcl-xL (C151I/E7C) in lipid vesicles did not produce cross-linked dimer,
while a low level of cross-linked dimer was observed with Bcl-xL
(C151I/N175C). This suggests that Glu7 at the N-terminus of two Bcl-xL
are far apart, while Asn175 onα6-helix of two Bcl-xL are in proximity in
the lipid vesicles [15]. As the spacer arm length of the cross-linker 1,4-
Bis-Maleimidobutane (BMB) used in the previous study is 10.9 Å [15],
the distance between Asn175 of two Bcl-xL subunits should be around
11 Å. The cross-linking of Cys151 and Asn185 by CuP in our present
work indicates that the distances between Cys151 and Asn185 of two
Bcl-xL subunits are in the range of 3–4 Å. Therefore, Cys151 or Asn185
of two Bcl-xL subunits are closer than the Asn175 in membranes. Our
work, together with the previous studies, indicates that α5-helices
and α6-helices are in close proximity upon membrane insertion. As
Bcl-xL and Bax share some important structure properties in lipids
[16], the structure characterized by α5–α5 and α6–α6 helices
interactions for Bcl-xL may have implications in the study of Bax
oligomerization and pore formation. Here, it should be noticed that
the α5–α5 and α6–α6 helices interactions can be characteristic of
an intermediate structure, which may be sufﬁciently speciﬁc and
stable to be trapped through chemical cross-linking. As there is no
evidence showing that the two types of interactions exist simulta-
neously, they do not necessarily correspond to the same interme-
diate structure of Bcl-xL protein.
As shown by the domain swapped structure of Bcl-xL homodimer
(Fig. 3B), Cys151 of two monomeric subunits are far apart from each
other and cannot form disulﬁde bond with oxidative agents (Fig. 2D,lane 2). However, the two cysteines can be cross-linked by CuP after
incubation with LUV (Fig. 2D, lane 4). Besides, the FRET based binding
assay demonstrates that the BH3-peptide binding hydrophobic
grooves which are intact in the domain swapped dimer are disrupted
after membrane insertion (Fig. 6). Both results suggest that the
domain swapped dimer undergoes conformational change after
membrane insertion. Bcl-xL most likely forms pores in a way distinct
from domain swapping in membranes.
Recently, the process of Bax activation, permeabilization, and
inhibition by Bcl-xL has been studied by ﬂuorescence techniques with
puriﬁed proteins and liposomes [11], showing that membrane-bound
tBid interacts with Bax and promotes its membrane insertion,
oligomerization and pore formation. Even after oligomerization and
pore formation of Bax, substoichiometric quantities of tBid remains
associatedwith Bax on themembranes. Bcl-xL can prevent the process
by directly interacting with tBid [8]. As shown by our FRET-based
binding assay, the BH3-peptide binding pocket in Bcl-xL is disrupted
upon membrane insertion. If Bcl-xL behaves similarly at low pH as it
does at physiological pH, the membrane-bound Bcl-xL should bind to
tBid through protein regions other than the BH3 domain of tBid and
the hydrophobic pocket of Bcl-xL.
Acknowledgements
We appreciate Prof. Junying Yuan for the kind gift of the Bcl-xL
plasmid on pET32b. We thank Prof. Ziwei Huang and Dr. Fernando R.
Pinacho-Crisostomo for critical reading of this manuscript. The work
was supported by CAS Introducing Outstanding Oversea Scientists
Project, NSFC Innovation Program for Research Group (Grant
20721003), CAS Knowledge Innovation Program (Grant KSCX2-YW-
R-18) and Shanghai Institute of Materia Medica.
References
[1] A.M. Petros, A. Medek, D.G. Nettesheim, D.H. Kim, H.S. Yoon, K. Swift, E.D.
Matayoshi, T. Oltersdorf, S.W. Fesik, Solution structure of the antiapoptotic
protein bcl-2, Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 3012–3017.
[2] S.W. Muchmore, M. Sattler, H. Liang, R.P. Meadows, J.E. Harlan, H.S. Yoon, D.
Nettesheim, B.S. Chang, C.B. Thompson, S.L. Wong, S.L. Ng, S.W. Fesik, X-ray and
NMR structure of human Bcl-xL, an inhibitor of programmed cell death, Nature
381 (1996) 335–341.
[3] M. Suzuki, R.J. Youle, N. Tjandra, Structure of Bax: coregulation of dimer formation
and intracellular localization, Cell 103 (2000) 645–654.
[4] G.R. Thuduppathy, O. Terrones, J.W. Craig, G. Basanez, R.B. Hill, The N-terminal
domain of Bcl-xL reversibly binds membranes in a pH-dependent manner,
Biochemistry 45 (2006) 14533–14542.
[5] S.L. Schendel, Z. Xie, M.O. Montal, S. Matsuyama, M. Montal, J.C. Reed, Channel
formation by antiapoptotic protein Bcl-2, Proc. Natl. Acad. Sci. U. S. A. 94 (1997)
5113–5118.
[6] A.J. Minn, P. Velez, S.L. Schendel, H. Liang, S.W. Muchmore, S.W. Fesik, M. Fill, C.B.
Thompson, Bcl-x(L) forms an ion channel in synthetic lipid membranes, Nature
385 (1997) 353–357.
[7] B. Antonsson, F. Conti, A. Ciavatta, S. Montessuit, S. Lewis, I. Martinou, L.
Bernasconi, A. Bernard, J.J. Mermod, G. Mazzei, K. Maundrell, F. Gambale, R.
Sadoul, J.C. Martinou, Inhibition of Bax channel-forming activity by Bcl-2, Science
277 (1997) 370–372.
[8] L.P. Billen, C.L. Kokoski, J.F. Lovell, B. Leber, D.W. Andrews, Bcl-XL inhibits
membrane permeabilization by competing with Bax, PLoS Biol. 6 (2008) e147.
[9] R.F. Epand, J.C. Martinou, S. Montessuit, R.M. Epand, C.M. Yip, Direct evidence for
membrane pore formation by the apoptotic protein Bax, Biochem. Biophys. Res.
Commun. 298 (2002) 744–749.
[10] J. Peng, C. Tan, G.J. Roberts, O. Nikolaeva, Z. Zhang, S.M. Lapolla, S. Primorac, D.W.
Andrews, J. Lin, tBid elicits a conformational alteration in membrane-bound Bcl-2
such that it inhibits Bax pore formation, J. Biol. Chem 281 (2006) 35802–35811.
[11] J.F. Lovell, L.P. Billen, S. Bindner, A. Shamas-Din, C. Fradin, B. Leber, D.W. Andrews,
Membrane binding by tBid initiates an ordered series of events culminating in
membrane permeabilization by Bax, Cell 135 (2008) 1074–1084.
[12] K.G. Wolter, Y.T. Hsu, C.L. Smith, A. Nechushtan, X.G. Xi, R.J. Youle, Movement of
Bax from the cytosol to mitochondria during apoptosis, J. Cell Biol. 139 (1997)
1281–1292.
[13] B. Antonsson, S. Montessuit, B. Sanchez, J.C. Martinou, Bax is present as a high
molecular weight oligomer/complex in the mitochondrial membrane of apopto-
tic cells, J. Biol. Chem. 276 (2001) 11615–11623.
[14] G.R. Thuduppathy, J.W. Craig, V. Kholodenko, A. Schon, R.B. Hill, Evidence that
membrane insertion of the cytosolic domain of Bcl-xL is governed by an
electrostatic mechanism, J. Mol. Biol. 359 (2006) 1045–1058.
2395Y. Feng et al. / Biochimica et Biophysica Acta 1788 (2009) 2389–2395[15] J.W. O'Neill, M.K. Manion, B. Maguire, D.M. Hockenbery, BCL-XL dimerization by
three-dimensional domain swapping, J. Mol. Biol. 356 (2006) 367–381.
[16] A.J. Garcia-Saez, I. Mingarro, E. Perez-Paya, J. Salgado, Membrane-insertion
fragments of Bcl-xL, Bax, and Bid, Biochemistry 43 (2004) 10930–10943.
[17] M.G. Annis, E.L. Soucie, P.J. Dlugosz, J.A. Cruz-Aguado, L.Z. Penn, B. Leber, D.W.
Andrews, Bax forms multispanning monomers that oligomerize to permeabilize
membranes during apoptosis, EMBO J. 24 (2005) 2096–2103.
[18] Y. Feng, Z. Lin, X. Shen, K. Chen, H. Jiang, D. Liu, Bcl-xL forms two distinct
homodimers at non-ionic detergents: implications in the dimerization of Bcl-2
family proteins, J. Biochem. 143 (2008) 243–252.
[19] H.S. Garewal, A procedure for the estimation of microgram quantities of triton X-
100, Anal. Biochem. 54 (1973) 319–324.
[20] S.H. White, W.C. Wimley, A.S. Ladokhin, K. Hristova, Protein folding in
membranes: determining energetics of peptide-bilayer interactions, Methods
Enzymol. 295 (1998) 62–87.
[21] Y. Feng, X. Shen, K. Chen, H. Jiang, D. Liu, A new assay based on ﬂuorescence
resonance energy transfer to determine the binding afﬁnity of Bcl-xL inhibitors,
Biosci. Biotechnol. Biochem. 72 (2008) 1936–1939.
[22] A. Kaufmann, E.H. Manting, A.K. Veenendaal, A.J. Driessen, C. van der Does,
Cysteine-directed cross-linking demonstrates that helix 3 of SecE is close to helix
2 of SecY and helix 3 of a neighboring SecE, Biochemistry 38 (1999) 9115–9125.
[23] B. Hazes, B.W. Dijkstra, Model building of disulﬁde bonds in proteins with known
three-dimensional structure, Protein Eng. 2 (1988) 119–125.
[24] Y. Feng, L. Zhang, T. Hu, X. Shen, J. Ding, K. Chen, H. Jiang, D. Liu, A conserved
hydrophobic core at Bcl-xL mediates its structural stability and binding afﬁnity
with BH3-domain peptide of pro-apoptotic protein, Arch. Biochem. Biophys. 484
(2009) 46–54.
[25] F. Girard, V. Vachon, G. Prefontaine, L. Marceau, Y. Su, G. Larouche, C. Vincent, J.L.
Schwartz, L. Masson, R. Laprade, Cysteine scanning mutagenesis of alpha4, a
putative pore-lining helix of the Bacillus thuringiensis insecticidal toxin Cry1Aa,
Appl. Environ. Microbiol. 74 (2008) 2565–2572.
[26] P.K. Kim, M.G. Annis, P.J. Dlugosz, B. Leber, D.W. Andrews, During apoptosis bcl-2
changes membrane topology at both the endoplasmic reticulum and mitochon-
dria, Mol. Cell 14 (2004) 523–529.
[27] P.J. Dlugosz, L.P. Billen, M.G. Annis, W. Zhu, Z. Zhang, J. Lin, B. Leber, D.W. Andrews,
Bcl-2 changes conformation to inhibit Bax oligomerization, EMBO J. 25 (2006)
2287–2296.[28] E.H. Cheng, M.C. Wei, S. Weiler, R.A. Flavell, T.W. Mak, T. Lindsten, S.J. Korsmeyer,
BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and
BAK-mediated mitochondrial apoptosis, Mol. Cell 8 (2001) 705–711.
[29] L. Chen, S.N. Willis, A. Wei, B.J. Smith, J.I. Fletcher, M.G. Hinds, P.M. Colman, C.L.
Day, J.M. Adams, D.C. Huang, Differential targeting of prosurvival Bcl-2 proteins by
their BH3-only ligands allows complementary apoptotic function, Mol. Cell 17
(2005) 393–403.
[30] H. Zha, C. Aime-Sempe, T. Sato, J.C. Reed, Proapoptotic protein Bax hetero-
dimerizes with Bcl-2 and homodimerizes with Bax via a novel domain (BH3)
distinct from BH1 and BH2, J. Biol. Chem. 271 (1996) 7440–7444.
[31] T. Chittenden, C. Flemington, A.B. Houghton, R.G. Ebb, G.J. Gallo, B. Elangovan, G.
Chinnadurai, R.J. Lutz, A conserved domain in Bak, distinct from BH1 and BH2,
mediates cell death and protein binding functions, EMBO J. 14 (1995) 5589–5596.
[32] M. Sattler, H. Liang, D. Nettesheim, R.P. Meadows, J.E. Harlan, M. Eberstadt, H.S.
Yoon, S.B. Shuker, B.S. Chang, A.J. Minn, C.B. Thompson, S.W. Fesik, Structure of
Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis, Science
275 (1997) 983–986.
[33] H. Ji, A. Shekhtman, R. Ghose, J.M. McDonnell, D. Cowburn, NMR determination
that an extended BH3 motif of pro-apoptotic BID is speciﬁcally bound to BCL-XL,
Magn. Reson. Chem. 44 Spec No (2006) S101–S107.
[34] P.H. Schlesinger, A. Gross, X.M. Yin, K. Yamamoto, M. Saito, G. Waksman, S.J.
Korsmeyer, Comparison of the ion channel characteristics of proapoptotic BAX
and antiapoptotic BCL-2, Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 11357–11362.
[35] S.L. Schendel, R. Azimov, K. Pawlowski, A. Godzik, B.L. Kagan, J.C. Reed, Ion channel
activity of the BH3 only Bcl-2 family member, BID, J. Biol. Chem. 274 (1999)
21932–21936.
[36] S. Matsuyama, S.L. Schendel, Z. Xie, J.C. Reed, Cytoprotection by Bcl-2 requires the
pore-forming alpha5 and alpha6 helices, J. Biol. Chem. 273 (1998) 30995–31001.
[37] S. Nouraini, E. Six, S. Matsuyama, S. Krajewski, J.C. Reed, The putative pore-
forming domain of Bax regulates mitochondrial localization and interaction with
Bcl-X(L), Mol. Cell. Biol. 20 (2000) 1604–1615.
[38] G. Heimlich, A.D. McKinnon, K. Bernardo, D. Brdiczka, J.C. Reed, R. Kain, M. Kronke,
J.M. Jurgensmeier, Bax-induced cytochrome c release frommitochondria depends
on alpha-helices-5 and -6, Biochem. J. 378 (2004) 247–255.
[39] C.M. Franzin, J. Choi, D. Zhai, J.C. Reed, F.M. Marassi, Structural studies of apoptosis
and ion transport regulatory proteins in membranes, Magn. Reson. Chem. 42
(2004) 172–179.
